ReviewChemMedChem2017
The Drug Discovery and Development Industry in India-Two Decades of Proprietary Small-Molecule R&D.
Review in ChemMedChem, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Review
- Appraising the visibility, relevance and impacts of clinical pharmacology.British journal of clinical pharmacology · 2025Review
- Mitigating inequitable access to appropriate antibiotics in low- and middle-income countries.JAC-antimicrobial resistance · 2025Review
- Rising pharmaceutical innovation in the Global South: a landscape study.Journal of pharmaceutical policy and practice · 2023Article
- Navigating the open innovation paradox: an integrative framework for adopting open innovation in pharmaceutical R&D in developing countries.The Journal of technology transfer · 2022Article
- Anti-Diabetic Activity of Bioactive Compound Extracted fromPlants (Basel, Switzerland) · 2022Article
- The role of superstition in the placebo effect on memory performance.Cognitive processing · 2021Article
- ICMR National Virtual Centre for Clinical Pharmacology with Network of Rational Use of Medicines & Product Development Centres.The Indian journal of medical research · 2021Article
- The work, goals, challenges, achievements, and recommendations of orphan medicinal product organizations in India: an interview-based study.Orphanet journal of rare diseases · 2019Article
- Need for alternatives to animals in experimentation: An Indian perspective.The Indian journal of medical research · 2019Article
- Patient-driven initiatives for prioritizing drug discovery for rare diseases.The Indian journal of medical research · 2019Article
- Unleashing biotech's crouching tiger.Nature biotechnology · 2018Article
- Unraveling the Metabolic Routes of Retapamulin: Insights into Drug Development of Pleuromutilins.Antimicrobial agents and chemotherapy · 2018Article
- The Drug Discovery and Development Industry in India-Two Decades of Proprietary Small-Molecule R&D.ChemMedChem · 2017Review
- A two-year evaluation of the minutes of Investigational New Drug committee meetings.Perspectives in clinical researchArticle
- Clinical trials and healthcare needs in India: A difficult balancing act but opportunities abound!Perspectives in clinical researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review provides a comprehensive survey of proprietary drug discovery and development efforts performed by Indian companies between 1994 and mid-2016. It is based on the identification and detailed analysis of pharmaceutical, biotechnology, and contract research companies active in proprietary new chemical entity (NCE) research and development (R&D) in India. Information on preclinical and clinical development compounds was collected by company, therapeutic indication, mode of action, target class, and development status. The analysis focuses on the overall pipeline and its evolution over two decades, contributions by type of company, therapeutic focus, attrition rates, and contribution to Western pharmaceutical pipelines through licensing agreements. This comprehensive analysis is the first of its kind, and, in our view, represents a significant contribution to the understanding of the current state of the drug discovery and development industry in India.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.